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Introduction
HIV is a neurotropic virus that enters the brain right after infection. In the brain, HIV repli-
cates in macrophages, microglia and small number of astrocytes (4.7 ± 2.8% in vitro and 8.2 ±
3.9 in vivo) (Eugenin et al., 2011) causing inflammatory and neurotoxic host responses. Severe
neurological disorders caused by HIV are collectively known as HIV-associated neurocognitive dis-
orders (HAND). HAND is characterized by development of abnormal reduction of motor speed,
concentration, and memory. HAND consists of several clinical forms ranging from asymptomatic
neurocognitive impairment (ANI), minor neurocognitive disorder (MND) to the most severe HIV-
associated dementia (HAD) (McArthur and Brew, 2010). HIV-encephalitis (HIVE) is the main
cause of HAND and the most common neurologic disorder of the brain in HIV-1 infection. HIV-1
exhibits extensive genetic variation worldwide and is categorized into three groups (M, O, and N)
and genetically into nine different subtypes (A–K). Of these, clades B and C represent the majority
(>86%) of circulating HIV-1 variants (Osmanov et al., 2002). While HIV-1 clade B is predominant
in North America, Western Europe, and Australia; clade C is common in Southern and East Africa,
India andNepal (responsible for around half of all HIV infections). HIV-1 clade B has been reported
to be more neuropathogenic than clade C (Atluri et al., 2013; Samikkannu et al., 2014). Before the
worldwide use of highly antiretroviral therapy (HAART), approximately, 20–30% of individuals
with advanced HIV-1 clade B infection showed symptoms of HAD (Gonzalez-Scarano andMartin-
Garcia, 2005; Kaul et al., 2005). Although the prevalence of HAD has decreased intensely after the
introduction of HAART, 40–50% of HIV positive patients still suffer from HAND (Sacktor et al.,
2001; Sacktor, 2002; McArthur, 2004; Antinori et al., 2007; Ellis et al., 2007). In developed coun-
tries, about 30% of HIV-positive individuals are intravenous drug abusers, which place them in a
higher risk for HAND (Miro et al., 2003; Beyrer et al., 2010). Cocaine and marijuana are the most
common drugs of abuse among HIV patients, whereas opioids are abused only by a small num-
ber of patients (Kuo et al., 2004; Cook et al., 2007; Korthuis et al., 2008). Overall, several drugs of
abuse such as tobacco, stimulants, cannabinoids, opioids and alcohol are found to be consumed
among HIV infected individuals, having an effect on synaptic plasticity and development found in
the brain (Hauser and Knapp, 2014). Figure 1 is showing different neurotoxic mechanisms of drugs
of abuse in HIV infection which may lead to the impaired neurocognitive functions.
Nicotine and HIV
Recently, in nicotine and HIV infected SK-N-MC cells, an up-regulation of HDAC2 was observed
(Atluri et al., 2014). HDAC2 overexpression has been reported in depleted memory forma-
tion, synaptic plasticity and dendritic spine density (Guan et al., 2009). Nevertheless, use of
nicotine in infected patients can have beneficial outcomes on neurological deficits that were
HIV-1 induced (Cao et al., 2013). In nicotine injected HIV-1 transgenic rats brain regions, such
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FIGURE 1 | Schematic representation of neurotoxic mechanisms of different illicit drugs of abuse in HIV infection.
as in the prefrontal cortex, Wnt/β-catenin signaling has shown
improvement by restoring the down-regulation of Axin1, Wnt5a,
Wnt7a and the up-regulation of Gnao1 (Cao et al., 2013). This
signaling pathway plays an important role in the early devel-
opment of the nervous system, in which a neuroprotective out-
come in adults is established after the activation of this pathway
(Nave and Trapp, 2008). These results are important since central
demyelination and neurodegeneration have been observed in
HIV-1 infected individuals. In the dorsal hippocampus, CREB
signaling has also been restored, in which the decreased expres-
sion of calcium sensor proteins, Calm3 and Cabp1, was regulated
to normal levels. This signaling pathway is significant in neu-
ronal survival and long-term synaptic plasticity. In the dorsal
striatum, nicotine has also shown to restore the function of the
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tricarboxylic acid (TCA) cycle and its related pathways, such as
the down-regulation of Idh3B and up-regulation of Ndufs4 that
came back to normal levels (Cao et al., 2013).
Psychostimulants and HIV
Stimulants such as cocaine indicated to be involved in up-
regulation of macrophage activation marker human leukocyte
antigen (HLA)-DR and increased HIV replication in mono-
cytes, and even astrocytes in vitro (Dhillon et al., 2007). Addi-
tionally, cocaine can induce HIV infection by the up-regulation
of dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN), which is another HIV co-
receptor (Nair et al., 2004). Cocaine can also induce monocyte
transendothelial migration, expression of endothelial adhesion
molecules, and disruption of intercellular junctions in the blood
brain barrier (BBB) in vitro (Fiala et al., 2005). HIV patients with
cocaine dependence reported to have a greater neurocognitive
impairment and poorer HAART adherence compared to non-
drug users (Meade et al., 2011). Dendritic varicosity formation
was enhanced in primary hippocampus neurons in the presence
of HIV-1 envelope glycoprotein gp120 and cocaine (Yao et al.,
2009). These findings proof that cocaine intensifies HIV infection
and neuronal damage.
On the other hand, methamphetamine (meth) is a neu-
rotoxic drug that injures dopaminergic neurons and reduces
dopamine as well as norepinephrine in the brain (McCann et al.,
1998). Moreover, in HIV infected meth abusers, a more cog-
nitive impairment was related to a smaller hippocampal vol-
ume (Berman et al., 2008). The expression of HIV co-receptors,
CXCR4 and CCR5, and HIV replication in astrocytes were both
increased in presence of meth (Nair et al., 2009). BBB dys-
function and an increase in the expression of pro-inflammatory
cytokinesis were observed, which can lead to meth-neurotoxicity
(Czub et al., 2001; Nath et al., 2002). Meth and gp120 cooper-
ated to induce interleukin-6 (IL-6) and cytochrome P450 2E1
(CYP2E1) in astrocytes (Shah et al., 2013). CYP2E1 generated
free electrons and reactive oxygen species (ROS) through its reac-
tion cycle. Further, caspase-3 activity increased, leading to DNA
fragmentation and apoptosis in astrocytes (Shah et al., 2013).
The expression of ZO-1, claudin-3, claudin-5, and JAM-2 also
decreased in combination of Meth and gp120 or Tat (Maha-
jan et al., 2008; Banerjee et al., 2010). Levels of matrix metallo-
proteinase 2 (MMP-2) and MMP-9 secretions increased in the
presence of meth and Tat treatment (Conant et al., 2004). These
data then proofs exacerbation of neurotoxicity in HIV and meth
combination.
Cannabinoids and HIV
The consumption of cannabinoids, in HIV infected individuals
was reported to modify inflammatory and neurotoxic processes.
Studies on HIV gp120 treated cells demonstrated degradation
in the synaptic network of hippocampal neurons (Kim et al.,
2011). These occurred when activation of CXCR4, triggered cell
signaling pathways and the release of IL-1β (Yi et al., 2004). This
β-chemokine is responsible for mediation of synapse loss, which
activates an ubiquitin ligase and the N-methyl-D-aspartate
(NMDA) receptor. This receptor is responsible for the control of
memory function and synaptic plasticity. The synapse loss was
said to be a protective mechanism rather than an agonal event,
which prevents cells from being over stimulated (Kim et al.,
2011).
However, the cannabinoid receptor full agonist (Win55212-2)
functioned as a protector for hippocampal neurons against
gp120-induced IL-1β production and synapse loss. This protec-
tion has been reported to be mediated by the CB2 cannabinoid
receptor, not the CB1. However, in exposure to the HIV-1 pro-
tein Tat, Win55212-2 did not inhibit synaptic loss (Kim et al.,
2011). It was also reported that the cannabinoid CB2 receptor
agonist (AM1241) intensifies neurogenesis in vivo and reduces
astrogenesis and gliogenesis in the hippocampus of GFAP/Gp120
transgenic mouse model (Avraham et al., 2014). This is an impor-
tant research content in the medical field for the future treatment
of neurodegenerative diseases and related disorders.
Moreover, the consumption of marijuana and its effects on
cognitive function is controversial. Marijuana consumption is
a common practice in HIV-infected individuals for different
interests, such as recreational and medicinal purposes. However,
reports are scanty on the impact of marijuana on cognitive func-
tions in these subjects. In a cohort study, the measurement of
cognitive impairment demonstrated synergistic effects of mar-
ijuana consumption in individuals with advanced HIV disease
whereas minimal impact on uninfected or those at early stages
of HIV infection (Cristiani et al., 2004).
Opioids and HIV
HIV viral proteins and opioid drugs are known as cofactors for
HIV infection because they act in synergy, leading to a greater
immunosuppression. HIV-1 Tat and morphine demonstrated a
synergistic effect in the up-regulation of inflammatory cytokines
and chemokines as well as a reduction in total spine density (Fit-
ting et al., 2011). This was observed when µ-opioid receptor
(MOPr) interacted with glutamatergic signals that came from α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors (Liao et al., 2005). The over activation of NMDA recep-
tor by Tat (Li et al., 2008), caused an excitotoxic manifestation
that inhibited ATP production and disruption in cellular ener-
getics (Perry et al., 2005). Fitting et al. reported a novel finding on
HIV-1 Tat and morphine-induced synaptodendritic injury medi-
ated by increased intracellular sodium ([Na(+)]i) and calcium
([Ca(2+)]i) in dendrites (Fitting et al., 2014).
In addition, the disturbance of synaptic transmissions in dor-
solateral prefrontal cortex (DLPFC) has been observed in sub-
jects that exhibit HIV encephalitis (HIVE) or HIV-associated
neurocognitive disorders (HAND). In HIVE patients, expression
of preproenkephalin (PENK), an opioid neurotransmitter, was
reduced and interferon regulatory factor 1 (IRF1) expression was
increased (Gelman et al., 2012); these are related neuropatholog-
ically to HIVE.
Alcohol Dependence and HIV Infection
It has been reported that lifetime alcohol dependence is able
to impair memory, attention and learning. However, cognitive
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dysfunctions are not all transient (Darke et al., 2000). Although
restraint demonstrated the recovery of psychomotor skills and
short-term memory; long-term memory injuries were observed
to last up to 7 years (Brandt et al., 1983). In a comparative
study between HIV-infected and uninfected individuals that had
an alcohol dependence history, major cognitive impairment in
HIV-infected group was observed within the domains of reac-
tion time, auditory processing, and verbal reasoning, whereas no
major impairments were observed in the other group. Thus, this
showed the synergistic effects that HIV and alcohol have on the
central nervous system (CNS) (Green et al., 2004).
Clinical Studies on Effect of Drugs of
Abuse in HIV Associated Neurocognitive
Impairment
Several studies have associated cocaine, methamphetamine and
opioid use with the aggravation of the risk for neurocognitive
impairment and neuronal injury in HIV infected individuals
(Martin-Thormeyer and Paul, 2009; Banerjee et al., 2011; Byrd
et al., 2011; Dutta and Roy, 2012). Nonetheless, a recent large
cohort study found that participants with histories of substance
use (alcohol, cocaine, cannabis, opiates, and methamphetamine)
did not exhibit higher rates of neurocognitive or functional
impairment in everyday life (Byrd et al., 2011). The majority of
these individuals were not current users and less than a third
reported using illicit substances within the last year. Accord-
ing to the authors, continuous phases of drug abstinence might
be enough for a full or partial recovery from neurocognitive
impairment. These results are consistent with another longitu-
dinal study, in which a neurocognitive function improvement
was observed in long-term abstinent meth users (average of 13
months) in comparison with non-abstinent meth users (Iudicello
et al., 2010). These findings propose that drugs of abuse might
have a limited legacy outcome on neurocognitive injury in HIV
infected individuals and that recent substance use may be more
relevant to modulating HIV neuropathogenesis. Further sup-
porting a role for drugs of abuse increasing neuroinflammation
and associated neurodegeneration, HIV-encephalitis diagnosis is
more frequent in HIV positive individuals who abuse drugs in
comparison to HIV positive controls (Buch et al., 2012; Liu et al.,
2012).
Conclusions
An understanding of the close and bidirectional relationship
between cognitive impairment and HIV risk factors is essen-
tial to efficiently reduce HIV risk. Clearly, the use of drugs of
abuse plays a critical role in HIV infected individuals, affecting
their neurological functioning and pathogenesis of HIV. Loss
of synaptic connections has been associated with HIV-1 associ-
ated dementia (HAD). However, since there are inhibitory and
excitatory connections, then this synapse loss, induced by HIV-
1, Tat, gp120 proteins in association with drugs of abuse, is
reversible. These data contribute to the improvement of neu-
ropathological outcomes in HIV individuals by offering new
insights for possible medical treatments that will target inhibitory
synapses among other techniques to treat HAD, HIVE, HAND
and related neurodegenerative diseases in drug abusing patients.
Further studies exploring the specific effects of applying cognitive
remediation approaches in HIV-specific interventions should be
directed.
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